|
Active substance |
Gilteritinib (ASP2215) |
|
Holder |
Astellas Pharma Tech Co., Ltd. |
|
Status |
Running |
|
Indication |
treatment of patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) without access to comparable or alternative therapy. |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
27/04/2020 |
Gilteritinib (ASP2215)
Last updated on 13/04/2021